The recent US Food and Drug Administration (FDA) approval of anifrolumab for the treatment of systemic lupus erythematosus (SLE) came a decade after the approval of human monoclonal antibody belimumab.
In this episode of the Rheumatology Advisor podcast, we speak with Mary K. Crow, MD, who provides a deeper insight into the evolution of lupus treatments over the years, with a focus on the history, barriers in research, information regarding the anifrolumab approval, and the future of drug development in SLE.
We also present the perspectives of a patient with lupus; Christele Felix serves as a Patient Advocate for Lupus Studies (PAL) for the Lupus Research Alliance, provides peer support for those interested in learning about clinical trials in lupus, and has presented on various topics, including health disparities, at the American College of Rheumatology (ACR) annual conference.
Transcript for this episode will be available shortly.
Mary Crow, MD, is physician-in-chief emerita at Hospital for Special Surgery (HSS), professor of medicine in the Division of Rheumatology of the Department of Medicine at Weill Cornell Medical College, and attending physician at New York Presbyterian Hospital and HSS. She is also the director of the Autoimmunity and Inflammation Research Program and co-director of the Mary Kirkland Center for Lupus Research at the HSS Research Institute.
Dr Crow holds the Benjamin M. Rosen Chair in Immunology and Inflammation Research at HSS. She is also the former co-chair of the Lupus Research Alliance Scientific Advisory Board, a role she performed for more than a decade.